Longjiang Shao1, Nermin Kahraman2, Ge Yan1, Jianghua Wang1, Bulent Ozpolat2, Michael Ittmann1. 1. Department of Pathology and Immunology, Baylor College of Medicine, Michael E. DeBakey Department of Veterans Affairs Medical Center, Houston, Texas. 2. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: The TMPRSS2/ERG (TE) fusion gene is present in half of the prostate cancers (PCas). The TMPRSS2 and ERG junction of the fusion messenger RNA (mRNA) constitutes a cancer-specific target. Although docetaxel-based chemotherapy is the second line of therapy following development resistance to androgen ablation therapies, it is not curative. Therefore, the development of nontoxic novel monotherapies for targeting TE mRNA in PCa patients and for increasing the clinical efficacy of docetaxel treatment are needed. METHODS: We evaluated multiple approaches to enhance the delivery of TE small interfering RNA (siRNA) containing liposomes including PEGylation, topical treatment with nitroglycerin (NG) to increase permeability and retention, and three different PEG modifications: folate, RGD cyclic peptide, and a bFGF fibroblast growth factor receptor-targeting peptide. The efficacy of the optimized TE siRNA liposome in combination with docetaxel was then evaluated in vivo with or without topical NG in vivo using a VCaP xenograft model. TE fusion protein knockdown in residual tumors was assessed using Western blotting and immunohistochemistry. RESULTS: In vivo therapeutic targeting of TE fusion gene by systemic delivery of RGD-peptide-coated liposomal siRNA nanovectors led to sustained target silencing, suppressed tumor growth in xenograft models and enhanced the efficacy of docetaxel chemotherapy. Simultaneous application of the vasodilator NG to the skin further increased tissue the delivery of siRNA and enhanced target knockdown. CONCLUSION: TE-targeted gene silencing therapy using liposomal nanovectors is a potential therapeutic strategy as a monotherapy and to enhance the efficacy of chemotherapy in patients with advanced PCa.
BACKGROUND: The TMPRSS2/ERG (TE) fusion gene is present in half of the prostate cancers (PCas). The TMPRSS2 and ERG junction of the fusion messenger RNA (mRNA) constitutes a cancer-specific target. Although docetaxel-based chemotherapy is the second line of therapy following development resistance to androgen ablation therapies, it is not curative. Therefore, the development of nontoxic novel monotherapies for targeting TE mRNA in PCa patients and for increasing the clinical efficacy of docetaxel treatment are needed. METHODS: We evaluated multiple approaches to enhance the delivery of TE small interfering RNA (siRNA) containing liposomes including PEGylation, topical treatment with nitroglycerin (NG) to increase permeability and retention, and three different PEG modifications: folate, RGD cyclic peptide, and a bFGF fibroblast growth factor receptor-targeting peptide. The efficacy of the optimized TE siRNA liposome in combination with docetaxel was then evaluated in vivo with or without topical NG in vivo using a VCaP xenograft model. TE fusion protein knockdown in residual tumors was assessed using Western blotting and immunohistochemistry. RESULTS: In vivo therapeutic targeting of TE fusion gene by systemic delivery of RGD-peptide-coated liposomal siRNA nanovectors led to sustained target silencing, suppressed tumor growth in xenograft models and enhanced the efficacy of docetaxel chemotherapy. Simultaneous application of the vasodilator NG to the skin further increased tissue the delivery of siRNA and enhanced target knockdown. CONCLUSION:TE-targeted gene silencing therapy using liposomal nanovectors is a potential therapeutic strategy as a monotherapy and to enhance the efficacy of chemotherapy in patients with advanced PCa.
Authors: Chad V Pecot; George A Calin; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood Journal: Nat Rev Cancer Date: 2010-12-16 Impact factor: 60.716
Authors: J Clark; S Merson; S Jhavar; P Flohr; S Edwards; C S Foster; R Eeles; F L Martin; D H Phillips; M Crundwell; T Christmas; A Thompson; C Fisher; G Kovacs; C S Cooper Journal: Oncogene Date: 2006-10-16 Impact factor: 9.867
Authors: Tai-Tu Lin; Tong Zhang; Reta B Kitata; Tao Liu; Richard D Smith; Wei-Jun Qian; Tujin Shi Journal: Mass Spectrom Rev Date: 2021-10-31 Impact factor: 9.011
Authors: Bharat K R Chaganty; Songbo Qiu; Yang Lu; Gabriel Lopez-Berestein; Bulent Ozpolat; Zhen Fan Journal: Cancer Immunol Immunother Date: 2021-11-03 Impact factor: 6.630
Authors: Julio M Rios De La Rosa; Alice Spadea; Roberto Donno; Enrique Lallana; Yu Lu; Sanyogitta Puri; Patrick Caswell; M Jayne Lawrence; Marianne Ashford; Nicola Tirelli Journal: Sci Rep Date: 2020-09-02 Impact factor: 4.379